Assessment of the efficacy of the use of zoledronic acid in the prevention of aromatase inhibitor-associated bone loss in postmenopausal women with hormone receptor-positive breast cancer who received letrozole as adjuvant therapy

Trial Profile

Assessment of the efficacy of the use of zoledronic acid in the prevention of aromatase inhibitor-associated bone loss in postmenopausal women with hormone receptor-positive breast cancer who received letrozole as adjuvant therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2013

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms Z-FAST Study-Japan
  • Most Recent Events

    • 31 May 2013 Interim results at 36 months presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2013 Status changed from completed to active, no longer recruiting.
    • 01 Jun 2012 Results published in the Breast Cancer Research and Treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top